Distinctive Clinical Effects of Haemorrhagic Markers in Cerebral Amyloid Angiopathy

Outcome markers for clinical trials in cerebral amyloid angiopathy.

Efforts are underway for early-phase trials of candidate treatments for cerebral amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment. A major barrier to these trials is the absence of consensus on measurement of treatment effectiveness. A range of potential outcome markers for cerebral amyloid angiopathy can be measured against the ideal criteria of...

Clinical phenotypes of Cerebral Amyloid Angiopathy.

The term Cerebral Amyloid Angiopathy (CAA) is used to describe the pathological changes occurring in cerebral blood vessels, both leptomeningeal and cortical that result from the deposition of amyloid proteins. This CNS vasculopathy is associated with a spectrum of clinical phenotypes that include both ischemic and hemorrhagic presentations. Dementia, cognitive impairment and transient neurolog...

[Cerebral amyloid angiopathy: pathogenesis and clinical features].

Cerebral amyloid angiopathy.

Brain of a 66 year old woman with a four year history of progressive dementia with episodes of encephalopathy. Opposite: Multiple small, cystic, and occasionally confluent cortical scars (arrows) were restricted to the cerebrum and were due to cerebral amyloid angiopathy. Histological examination of the cortex in the postmortem brain showed numerous neuritic plaques and neurofibrillary tangles ...

Cerebral amyloid angiopathy

Cerebral amyloid angiopathy is increasingly recognized as a major cause of hemorrhagic stroke in the elderly as well as an important contributor to the growing challenge of vascular cognitive impairment, even in cerebral amyloid angiopathy patients without hemorrhagic stroke. Among the advances highlighted in this update are: (1) the importance of sulcal bleeding events in early recurrent hemor...